Eli Lilly and Co.

11. Nov. 2026, 23:03 UTC

Eli Lilly reports positive results from the TOGETHER-PsA trial, showing Taltz and Zepbound's efficacy in treating psoriatic arthritis with weight-related comorbidities.

9. Nov. 2026, 21:04 UTC

Eli Lilly reports positive Phase 3 trial results for Foundayo, showing significant reductions in obstructive sleep apnea severity among adults with obesity or overweight.

7. Nov. 2026, 00:02 UTC

Eli Lilly and Company announces agreement with Hims & Hers Health to expand access to medications Zepbound and Foundayo.

6. Nov. 2026, 23:02 UTC

Eli Lilly announces agreement with Hims & Hers to enhance access to medications Zepbound and Foundayo, with shares trading roughly flat in after-market hours.

5. Nov. 2026, 23:03 UTC

Eli Lilly shares are trading modestly lower in after-market hours, reflecting a broader market decline amid significant drops in major semiconductor stocks.

4. Nov. 2026, 23:02 UTC

Eli Lilly and Company shares gained modestly in after-market trading, remaining near the upper end of their one-month range following fluctuating returns.

3. Nov. 2026, 23:01 UTC

Eli Lilly and Company shares are trading modestly lower in after-market hours, retreating from a brief peak earlier in the session.

2. Nov. 2026, 23:06 UTC

Eli Lilly and Company is experiencing a modest increase in after-market trading, gaining slightly since Monday's close and positioned above its 20-day moving average.

30. Okt. 2026, 23:01 UTC

JP Morgan maintains Overweight rating on Eli Lilly and raises price target to $165, with shares trading modestly higher in after-market hours.

29. Okt. 2026, 23:03 UTC

Eli Lilly and Company shares advanced during after-market hours, reflecting a broader upward trend in the Pharmaceuticals sub-sector.

28. Okt. 2026, 23:02 UTC

Eli Lilly announces positive topline results from its Phase 3 trial comparing retatrutide to Ozempic in adults with type 2 diabetes.

27. Okt. 2026, 20:07 UTC

Eli Lilly announces a fourth-quarter 2026 dividend of $1.73 per share and reports strong Q2 results with net income of $7.09 billion.

23. Okt. 2026, 20:02 UTC

Eli Lilly and Co shares are declining, continuing a downward trend since Thursday's close, while the broader Pharmaceuticals sector is also lower.

22. Okt. 2026, 20:07 UTC

Eli Lilly breaks ground on a $5 billion manufacturing facility in Virginia, expected to create 650 permanent jobs and support U.S. manufacturing initiatives.

21. Okt. 2026, 20:07 UTC

Leerink Partners raised Eli Lilly's price target to $1.32k, while RBC Capital set a target of $1.5k, but shares are declining in today's session.

20. Okt. 2026, 23:02 UTC

Eli Lilly named RBC Capital's preferred pharmaceutical stock with a $1.5K price target, despite shares declining modestly in after-market hours.

19. Okt. 2026, 23:06 UTC

Eli Lilly announces positive Phase 3 SHINE-2 study results for Omvoh in pediatric ulcerative colitis, with 81% of participants achieving clinical response at Week 12.

17. Okt. 2026, 00:01 UTC

Eli Lilly and Co shares are lower in after-market hours, reflecting broader market declines amid stronger-than-expected inflation metrics and significant inflows in U.S. TIC Flows.

16. Okt. 2026, 23:06 UTC

Eli Lilly and Co shares are trading slightly lower in after-market hours, reflecting routine fluctuations amid a stable broader market context.

15. Okt. 2026, 23:11 UTC

Eli Lilly announces new data showing treatment goals achieved for ulcerative colitis and Crohn's disease patients with Omvoh after one year.

14. Okt. 2026, 23:42 UTC

Eli Lilly and Co's shares are trading lower in after-market hours, reflecting a broader market decline amid rising Treasury yields and inflation concerns.

13. Okt. 2026, 20:02 UTC

Eli Lilly announces a clinical trial collaboration with Prelude Therapeutics for a Phase 1 trial involving abemaciclib and imlunestrant, contributing to bearish sentiment.

12. Okt. 2026, 20:07 UTC

Eli Lilly gains support as RBC Capital reiterates Outperform rating with a $1.5K price target, following new data from the TOGETHER-PsO Phase 3b trial.

9. Okt. 2026, 20:07 UTC

Eli Lilly presents new data from its Phase 3b TOGETHER-PsO trial, showing significant biomarker changes with the combination of Taltz and Zepbound for psoriasis treatment.

8. Okt. 2026, 23:05 UTC

Eli Lilly and Co shares are trading lower in after-market hours, reflecting a decline since Thursday's close and fluctuating near the lower end of its recent range.

7. Okt. 2026, 23:06 UTC

Eli Lilly and Co is trading slightly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month trading range.

6. Okt. 2026, 20:07 UTC

Eli Lilly contributed to a $120 million Series B funding round for General Medicine, raising total funding to $152 million, amid positive market sentiment.

5. Okt. 2026, 23:06 UTC

Eli Lilly and Co is gaining after-hours as it plans to present new dermatology data at the 2026 Fall Clinical Dermatology Conference in October.

2. Okt. 2026, 20:07 UTC

Eli Lilly shares fell amid FDA approval of Jaypirca for chronic lymphocytic leukemia, which includes serious safety warnings, impacting market sentiment.

1. Okt. 2026, 23:06 UTC

Eli Lilly and Co is seeing a slight upward move in after-market trading, with prices fluctuating around the middle of its one-month trading range.